These data define a new intrinsic role for CNP in offsetting the pathogenesis of MASLD, hepatic fibrosis, and portal hypertension and the potential for targeting CNP signaling for treating these disorders. Here, CNP is linked to metabolic dysfunction-associated steatotic liver disease.